Insulin aspart: Difference between revisions
Brian Blank (talk | contribs) No edit summary |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 27: | Line 27: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
'''Insulin aspart''' (marketed by [[Novo Nordisk]] as "NovoLog®/NovoRapid") is a fast acting [[insulin analogue]]. It was created through [[recombinant DNA]] technology so that the amino acid, B28, which is normally [[proline]], is substituted with an [[aspartic acid]] residue. The sequence was inserted into the [[yeast]] genome, and the yeast expressed the insulin analogue, which was then harvested from a [[bioreactor]]. This analogue also prevents the formation of hexamers, to create a faster acting insulin. Can be used in CSII pumps and Flexpen, Novopen delivery devices for subcutaneous injection. <ref>{{cite web |url=http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a605013.html |title=Aspart® insulin (rDNA origin) injection |accessdate=2007-06-08 |format= |work= }}</ref> | '''Insulin aspart''' (marketed by [[Novo Nordisk]] as "NovoLog®/NovoRapid") is a fast acting [[insulin analogue]]. It was created through [[recombinant DNA]] technology so that the amino acid, B28, which is normally [[proline]], is substituted with an [[aspartic acid]] residue. The sequence was inserted into the [[yeast]] genome, and the yeast expressed the insulin analogue, which was then harvested from a [[bioreactor]]. This analogue also prevents the formation of hexamers, to create a faster acting insulin. Can be used in CSII pumps and Flexpen, Novopen delivery devices for subcutaneous injection. <ref>{{cite web |url=http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a605013.html |title=Aspart® insulin (rDNA origin) injection |accessdate=2007-06-08 |format= |work= }}</ref> | ||
| Line 39: | Line 39: | ||
{{Oral hypoglycemics and insulin analogs}} | {{Oral hypoglycemics and insulin analogs}} | ||
[[Category:diabetes]] | [[Category:diabetes]] | ||
Revision as of 16:26, 9 August 2012
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C256H387N65O79S6 |
| Molar mass | 5831.6 g/mol |
|
WikiDoc Resources for Insulin aspart |
|
Articles |
|---|
|
Most recent articles on Insulin aspart Most cited articles on Insulin aspart |
|
Media |
|
Powerpoint slides on Insulin aspart |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Insulin aspart at Clinical Trials.gov Trial results on Insulin aspart Clinical Trials on Insulin aspart at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Insulin aspart NICE Guidance on Insulin aspart
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Insulin aspart Discussion groups on Insulin aspart Patient Handouts on Insulin aspart Directions to Hospitals Treating Insulin aspart Risk calculators and risk factors for Insulin aspart
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Insulin aspart |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Insulin aspart (marketed by Novo Nordisk as "NovoLog®/NovoRapid") is a fast acting insulin analogue. It was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analogue, which was then harvested from a bioreactor. This analogue also prevents the formation of hexamers, to create a faster acting insulin. Can be used in CSII pumps and Flexpen, Novopen delivery devices for subcutaneous injection. [1]
According to JDRF, insulin aspart was approved for marketing in the United States by the Food and Drug Administration in June of 2000.
It has been debated whether or not insulin aspart (or NovoLog®/NovoRapid) should be refrigerated. Recent studies have shown that there is no difference, however insulin should not be stored in intense heat for a long period of time. This causes the hormone to reach a pre- boiling state, and separate. This can change the potency of the insulin, and it would no longer be as effective. A good rule of thumb is to keep the insulin at around room temperature or less.
References
- ↑ "Aspart® insulin (rDNA origin) injection". Retrieved 2007-06-08.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Diabetes
- Endocrinology